Novartis and Schwarz extend valsartan deal
The Spanish affiliate of Germany's Schwarz Pharma, CEPA Schwarz Pharma,has entered into an agreement with Novartis Farmaceutica to market a generic version of the latter's antihypertensive drug Diovan (valsartan), under the brand name Miten. The agreement also includes valsartan in combination with hydrochlorothiazide, marketed by Novartis as Co-Diovan and due to be sold by CEPA as Miten Plus.
The deal follows a previous alliance between the two companies signed in 1999, in which Schwarz licensed valsartan in Germany where it markets it as Provas (Marketletters passim).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze